ResearcherAffiliated Hospital of Guizhou Medical UniversityNo recent work listed

Zili Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0473-6395; OpenAlex author ID A5101950597. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2018: 2 papers

Papers 2

MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. Co-author DOI 10.1016/j.mcp.2018.06.003 ↗
Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Co-author DOI 10.3892/or.2018.6198 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chengyi Sun · 2 shared papers, 2018 · strength 0.18
- Paper MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. DOI 10.1016/j.mcp.2018.06.003 ↗
- Paper Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. DOI 10.3892/or.2018.6198 ↗
Haitao Zhu · 2 shared papers, 2018 · strength 0.18
- Paper MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. DOI 10.1016/j.mcp.2018.06.003 ↗
- Paper Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. DOI 10.3892/or.2018.6198 ↗
Chao Yu · 1 shared paper, 2018 · strength 0.10
- Paper MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. DOI 10.1016/j.mcp.2018.06.003 ↗
Yaozhen Pan · 1 shared paper, 2018 · strength 0.10
- Paper MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. DOI 10.1016/j.mcp.2018.06.003 ↗
Qianfan Liu · 1 shared paper, 2018 · strength 0.08
- Paper Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. DOI 10.3892/or.2018.6198 ↗
Liwen Chen · 1 shared paper, 2018 · strength 0.08
- Paper Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. DOI 10.3892/or.2018.6198 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.